Newsfeeds Archive - Spark Newswire

2 minute read

Industry Groups Back GSK’s Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer

June 20, 2:03 PM

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

GSK

2 minute read

Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products

By Vandana Singh

June 20, 1:53 PM

Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products.

JNJ

2 minute read

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount

By Vandana Singh

June 20, 1:46 PM

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

BMY

1 minute read

Johnson & Johnson’s Arthritis Drug Shows Potential In Crohn’s Disease

By Vandana Singh

June 20, 1:01 PM

Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints.

JNJ

2 minute read

What’s Going On With Neurological Disease Focused Trevena On Thursday?

By Vandana Singh

June 20, 12:50 PM

Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod.

NVS

1 minute read

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

June 20, 12:29 PM

Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.

JAZZ

1 minute read

Why Is Gilead Sciences Stock Trading Higher On Thursday?

By Vandana Singh

June 20, 12:00 PM

Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints, demonstrating superiority over daily Truvada and background HIV incidence.

GILD

2 minute read

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder

By Vandana Singh

June 20, 10:09 AM

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.

PTCT

2 minute read

What’s Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

By Vandana Singh

June 20, 9:43 AM

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.

TPST

2 minute read

Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer’s And Dementia Treatment

By Vandana Singh

June 20, 8:40 AM

Nexalin Technology has received U.S. patent for its non-invasive Deep Intracranial Frequency Stimulation device for Alzheimer's and dementia. The device is part of a market projected to reach over $28 billion by 2030.

NXL